1,125,933 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Norges Bank

Norges Bank bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,125,933 shares of the biopharmaceutical company’s stock, valued at approximately $802,036,000. Norges Bank owned 1.02% of Regeneron Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Howe & Rusling Inc. increased its position in shares of Regeneron Pharmaceuticals by 9.5% during the fourth quarter. Howe & Rusling Inc. now owns 506 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 44 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after purchasing an additional 393,997 shares during the period. NEOS Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 30.6% during the 4th quarter. NEOS Investment Management LLC now owns 17,650 shares of the biopharmaceutical company’s stock worth $12,573,000 after purchasing an additional 4,140 shares in the last quarter. UniSuper Management Pty Ltd raised its stake in shares of Regeneron Pharmaceuticals by 38.0% in the 4th quarter. UniSuper Management Pty Ltd now owns 7,306 shares of the biopharmaceutical company’s stock valued at $5,204,000 after purchasing an additional 2,013 shares during the period. Finally, Sava Infond d.o.o. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $492,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research reports. TD Cowen cut their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Down 0.7 %

Shares of REGN opened at $635.83 on Friday. The firm has a 50 day simple moving average of $684.76 and a two-hundred day simple moving average of $803.87. The company has a market cap of $69.51 billion, a P/E ratio of 16.61, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a one year low of $629.02 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.